E-mail:gzliang@cqu.edu.cn    Tel: (86)2365102507

List of peptide properties
DFBP ID - DFBPANCA0109(Anticancer peptide)
DFBP ID DFBPANCA0109
Peptide sequence VENLHLPLPLL
Type Native peptide
Peptide/Function name Anticancer peptide
Function-activity relationship
Main bioactivity Anticancer activity
Otheir bioactivity ACE-inhibitory activity [D1], Multifunctional activity [D2]
Calculated physicochemical properties
Three-letter amino acid Val-Glu-Asn-Leu-His-Leu-Pro-Leu-Pro-Leu-Leu
Single-letter amino acid VENLHLPLPLL
Peptide length 11
Peptide mass
Experimental mass Theoretical mass
N.D 1257.52 Da c
Net charge 0.00 c
Isoelectric point (pI) 5.17 c
IC50 N.D
pIC50 N.D
GRAVY 0.8909 c
Hydrophilic residue ratio 72.73% c
Peptide calculator
To calculate the physicochemical properties of bioactive peptide.
Peptide source & Food-borne protein(s) search
Classification Animal
Organism/Source Bovine milk
Precursor protein β-Casein
Residue position

f(145-155)

Precursor protein(s) search
Link-research
Link 1: DFBPANCA0094----Bovine----Casein protein
Biological/Functional activity & target protein
Anticancer activity

The peptides obtained from caseins selectively inhibited the enzymatic activities of prolyl-amino-peptidases, prolyl-amino- dipeptidases, and prolyl-endopeptidases in extracts of HT-29 and SW480 human colon carcinoma cells, but not in intact cells. They were not cytotoxic or growth inhibitory for these cells. Thus, the prolyl-rich selected peptides were good and selective inhibitors of MMPs and post-proline-cleaving proteases, demonstrating their potential to control inadequate proteolytic activity in the human digestive tract, without inducing cytotoxic effects.

Table 1 IC50 values for inhibition by casein-derived peptides of prolyl-specific proteolytic activities extracted from HT-29 cells a
Protein
Peptide code
sequence
IC50 ± SD (μM)
Gly-Pro-AMC
Z-Gly-Pro-AMC
αs1-Casein
Phe1
FVAPFPEVFG
1500 ± 120
60 ± 5
Phe2
ENLLRFFVAPFPEVFG
1000 ± 85
30 ± 3
Phe3
NENLLRFFVAPFPEVFG
1500 ± 100
50 ± 3
Phe4
LNENLLRFFVAPFPEVFG
1500 ± 120
30 ± 4
β-Casein
Leu1
NLHLPLPLL
1500 ± 150
150 ± 4
Leu2
ENLHLPLPLL
1900 ± 185
250 ± 15
Leu3
VENLHLPLPLL
1650 ± 145
250 ± 25

a Residual enzyme activity determined using either Gly-Pro-AMC or Z-Gly-Pro-AMC as substrate in the presence of increasing concentrations of peptides, then IC50 were determined graphically, as the peptide concentration able to inhibit 50% of the enzyme activity.

Specific target protein(s) N.D
Taste properties & Structure
Bitterness
Literature report N.D
Bitter prediction tools Bitter taste prediction
SMILES N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCC(=O)O)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC1=CN=C-N1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
Preparation method
Mode of preparation

Fermentation

Enzyme(s)/starter culture

Casein digestion was obtained by lactic acid bacteria and separated the peptides by chromatrography.

Stability & Cytotoxicity
Peptide stability
Literature report: N.D
EHP-Tool: Enzymatic Hydrolysis Prediction Tool (EHP-Tool)
Peptide cytotoxicity
Literature report:

The peptide was not cytotoxic or growth inhibitory for normal cells.

Prediction: ToxinPred
Additional information
Additional information N.D
Database cross-references
DFBP
[D1] DFBPACEI1438
[D2] DFBPMUFU0382
BIOPEP-UWM [D3] 8317
APD [D4] -
BioPepDB [D5] -
MBPDB [D6] -
Reference(s)
Primary literature Juillerat-Jeanneret L, Robert MC, Juillerat MA. Peptides from Lactobacillus hydrolysates of bovine milk caseins inhibit prolyl-peptidases of human colon cells. J Agric Food Chem. 2011 Jan 12;59(1):370-7.
PMID: 21126072
Other literature(s)

[1] Tauzin J, Miclo L, Gaillard JL. Angiotensin-I-converting enzyme inhibitory peptides from tryptic hydrolysate of bovine alphaS2-casein.[J]. Febs Letters, 2002, 531(2):369-374.
[2] Murray B A, Fitzgerald R J. Angiotensin converting enzyme inhibitory peptides derived from food proteins: biochemistry, bioactivity and production[J]. Current Pharmaceutical Design, 2007, 13(8):-.

PubDate 2011
Copyright © 2020. Record / license number: Chongqing ICP No. 2000214